Velicept Therapeutics, Inc. is a privately-held, clinical development company focused on advancing best-in-class compounds for the treatment of urological and gastrointestinal disorders. Its lead product, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).
| Website | http://www.velicept.com |
| Revenue | $1 million |
| Funding | $36 million |
| Employees | View employees |
| Founded | 2015 |
| Address | 640 Lee Rd, Ste 119, Wayne, Pennsylvania 19087, US |
| Phone | +1 484-318-2988 |
| Fax | (484) 324-7949 |
| Industry | Drug Manufacturing & Research, Health Care, Pharmaceuticals, Medical, Healthcare, Therapeutics |
| Competitors | Medtronic, Abbott, Boston Scientific, NeuroPace, electroCore, Inc., Soterix Medical, Axovant Sciences Ltd, NeuroSigma, ImThera Medical: Sleep Apnea Implant Therapy, Targacept, Inc. +35 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Velicept employee's phone or email?
Velicept Questions
The Velicept annual revenue was $1 million in 2026.
Velicept is based in Wayne, Pennsylvania.
The NAICS codes for Velicept are [325, 32541, 3254, 32].
The SIC codes for Velicept are [283, 28].
